Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Ovarian Neoplasms 5Neoplasms 5Colorectal Neoplasms 5Prostatic Neoplasms 4Glioblastoma 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Lung Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uveal Melanoma 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hypertension 1

Interventions

pembrolizumab 1lenvatinib 1cediranib 1Sorafenib 1Lenalidomide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid cancer, Hurthle cell × cediranib × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡